Colorectal Cancer Screening Simplified.
A non-invasive, blood-based test backed by FDA-approved science.
How It Works
Step 1: Simple Blood Draw. A routine blood sample is collected (at home or in-clinic).
Step 2: Biomarker Detection. Our lab analyzes the sample for methylated DNA specifically linked to colorectal cancer.
Step 3: Actionable Results. Results are delivered within 7-10 days, allowing you and your doctor to make informed decisions.
Two Ways to Access ColoHealth
Feature
ColoHealth Direct
ColoHealth for Physicians
Best For
Patients who want to take control without a primary care visit
Clinics looking to improve screening compliance in-house.
Collection
Patients who want to take control without a primary care visit
In-Office Draw or drop-ship kits directly to patients.
Cost
Fixed $299 self-pay; avoid insurance hassles.
Professional billing or direct clinic invoicing.
Odering
Patients who want to take control without a primary care visit
Integrated Physician Portal or manual order forms.
Reporting
Secure PDF sent directly to the patient.
Results Delivered to your office or directly to your patient. You choose.
Partner with us
Physician-Specific Benefits
Seamless Portal Integration: Manage patient orders, track sample status, and access documentation.
Flexible Sample Logistics: Choose to mail samples from your office or have our team handle the logistics directly with the patient.
Improved Compliance: Offer a solution to patients who have historically refused colonoscopies or stool-based tests (FIT/Cologuard).
Evidence-Based: Backed by a 99.7% Negative Predictive Value (NPV), giving you confidence in negative results for average-risk patients.
Is ColoHealth Right For You?
Are you avoiding colonoscopy?
Nervous about the procedure/prep or don’t want to take so much time out of your busy schedule?
Our Solution:
Convenience Without Compromise.
A simple blood test fits your life, not the other way around.
Grossed out about “Going #2 In a Box?”
Want a blood-test choice that is more convenient and less messy while still being non-invasive?
Our Solution:
No Mess, No Stress.
Professional blood draw performed by local patient service centers.
Does your insurance deductible (or lack thereof) pose a financial burden?
Are you okay with a self-pay test that you actually want to take when you want to take it?
Our Solution:
Affordable, Transparent Pricing
Straightforward, accessible and no hidden fees.
Want an accurate screening test YOU choose?
Based on FDA-approved and peer-reviewed science, every order and result is reviewed by Everly Health Systems' providers nationwide.
Our Solution:
Science You Can Trust.
Accuracy, safety, and clinical oversight you can rely on.
Find the Answers You Need
Whether you have a question about our testing solutions or need assistance with our services, we’re here to help. Share a few details below, and a member of the New Day team will reach out to you shortly.
What Can I Do Next?
You can order ColoHealth Direct today! visit our website ColoHealthy.com to place an order. If you are a Physician, contact us to find out how to join the program.
INDICATIONS FOR USE
ColoHealth Direct is a Laboratory Developed Test for the detection of methylated Septin 9. Methylated Septin 9 is a qualified predictor of early onset colorectal cancer.
ColoHealth Direct is intended for use in those who are age 50 or older, with no history of colon cancer, gastrointestinal abnormalities (such as IBS, Crohn’s disease, diverticulosis, etc), or symptoms of colon cancer (such as changes in bowel habits or blood in stool), no history of colon cancer in first degree relatives (mother, father, sibling), and no history of any hereditary cancer syndromes (such as Lynch syndrome).
Research has shown that testing for methylated Septin 9 may be beneficial for other populations such as those who are under age 50, those who may be symptomatic, those who have had a family history of cancer, or those who may have a history of hereditary cancer syndromes. Test performance in individuals under 50 is limited to retrospective case-control data in a study of 27 early onset colorectal cancer cases with a median age of 44.
WARNINGS, LIMITATIONS, & PRECAUTIONS
The ColoHealth Direct™ test is not intended to replace colorectal cancer screening tests that are recommended by appropriate guidelines (e.g., 2021 USPSTF guidelines) such as colonoscopy, sigmoidoscopy, and high sensitivity fecal occult blood testing. The ColoHealth Direct test is not intended for patients who are willing and able to undergo routine colorectal cancer screening tests that are recommended by appropriate guidelines.
There is limited research data currently available demonstrating that ColoHealth Direct could be indicated for those under age 50 and/or those with the following conditions: those with an elevated risk of developing CRC based on previous history of colorectal polyps, CRC or related cancers, inflammatory bowel disease (IBD), chronic ulcerative colitis, Crohn’s disease, familial adenomatous polyposis, family history of CRC, hereditary cancer syndrome (HNPCC or Lynch Syndrome), Peutz-Jeghers syndrome, MAP, Gardner’s syndrome, Turcot’s (Crail’s) syndrome, Cowden’s syndrome, Cronkhite-Canada syndrome, Neurofibromatosis, Familial Hyperplastic Polyposis, or in those with anorectal bleeding hematochezia, or with known iron deficiency anemia.
REFERENCES
Loomans-Kropp HA, Song Y, Gala M, Parikh AR, Van Seventer EE, Alvarez R, Hitchins MP, Shoemaker RH, Umar A. Methylated Septin9 (mSEPT9): A promising blood-based biomarker for the detection and screening of early-onset colorectal cancer. Cancer Res Commun. 2022 Feb;2(2):90-98. doi: 10.1158/2767-9764.crc-21-0142. Epub 2022 Feb 11. PMID: 35992328; PMCID: PMC9387652.
Song, L., Jia, J., Peng, X. et al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Sci Rep 7, 3032 (2017). https://doi.org/10.1038/s41598-017-03321-8
Hitchins MP, Vogelaar IP, Brennan K, Haraldsdottir S, Zhou N, Martin B, Alvarez R, Yuan X, Kim S, Guindi M, Hendifar AE, Kalady MF, DeVecchio J, Church JM, de la Chapelle A, Hampel H, Pearlman R, Christensen M, Snyder C, Lanspa SJ, Haile RW, Lynch HT. Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. BMJ Open Gastroenterol. 2019 May 28;6(1):e000299. doi: 10.1136/bmjgast-2019-000299. PMID: 31275589; PMCID: PMC6577308.